课题基金 / 基金详情

Sleep Apnea, PAP Therapy, and Kidney Function Trajectory

Sleep Apnea, PAP Therapy, and Kidney Function Trajectory
睡眠呼吸暂停、PAP 治疗和肾功能轨迹
批准号:
8765891
负责人:
Muna T Canales
金额:
$23.43万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-07-01 至 2016-06-30

项目摘要

项目成果

Muna T Canales的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):本研究的目的是确定睡眠呼吸暂停是否是慢性肾脏疾病(CKD)的一种新的、可改变的风险因素。我们建议对现有数据集进行研究,以帮助确定诊断为睡眠呼吸暂停的患者是否会加速肾功能丧失,以及睡眠呼吸暂停的气道正压通气(PAP)治疗是否会降低肾功能丧失率。我们将通过使用两个丰富和互补的数据集进行纵向分析来实现这些目标:威斯康星州睡眠队列和凯撒永久南加州(KPSC)人口研究数据库。 睡眠呼吸暂停是一种常见的疾病,影响五分之一的美国人,可以使用PAP疗法有效治疗。睡眠呼吸暂停与CKD的风险特征相似,包括高血压和糖尿病,这是终末期肾病(ESKD)的两个最常见原因。睡眠呼吸暂停对心血管、中枢神经和内分泌系统有害。睡眠呼吸暂停与CKD的关系尚不清楚。我们假设,在后来被诊断为呼吸暂停的个体和更严重的睡眠呼吸暂停个体中,将观察到更快的肾功能丧失率。我们假设PAP治疗将减缓肾功能丧失,并且有效的PAP治疗将比无效治疗更大程度地减缓肾功能丧失。 威斯康星州睡眠队列研究(WSCS)是一项持续20年的前瞻性研究,由NIH资助,对1,522名中年健康成人进行了定期评估,使用金标准测量、PAP治疗充分性测量和系列血清肌酐测试评估睡眠呼吸暂停严重程度,并据此估计肾功能。KPSC人口研究数据库包含超过100,000名睡眠呼吸暂停患者的经验证病例识别,包括诊断和PAP设备分发日期,以及完整的电子病历,包括临床获得的血清肌酐测试。在两个队列中,将根据估计的肾小球滤过率(eGFR)评估肾功能。我们将使用线性斜率和非线性混合模型对eGFR轨迹进行建模,以比较PAP治疗前后的eGFR趋势。在每个队列中,将构建一个非呼吸暂停对照组,并控制主要合并症。 我们打算通过这项研究直接为未来的有效性试验提供信息, 在干预和非干预地点之间,利用在大群体中的主动和被动数据收集,例如KPSC,对睡眠呼吸暂停的筛查和治疗进行比较。这项研究的结果有可能推动一个有前途的研究领域,最终可能改变高肾脏风险或确诊CKD患者的评估和治疗,以帮助预防相关的发病率和死亡率。
英文摘要
DESCRIPTION (provided by applicant): The purpose of this study is to determine if sleep apnea is a novel, modifiable risk factor for chronic kidney disease (CKD). We propose a study of existing data sets to help determine if kidney function loss is accelerated in patients who are diagnosed with sleep apnea, and if positive airway pressure (PAP) therapy for sleep apnea reduces the rate of kidney function loss. We will accomplish these aims through longitudinal analyses using two rich and complementary data sets: the Wisconsin Sleep Cohort and Kaiser Permanente Southern California (KPSC) Population Research Databases. Sleep apnea is common disorder affecting 1 in 5 Americans and can be effectively treated using PAP therapy. Sleep apnea shares a similar risk profile to CKD, including hypertension and diabetes, the two most common causes of end-stage kidney disease (ESKD). Sleep apnea is known to be deleterious to the cardiovascular, central nervous and endocrine systems. The relationship of sleep apnea to CKD is not yet clear. We hypothesize that a faster rate of kidney function loss will be observed in individuals who are later diagnosed with apnea and in individuals with more severe sleep apnea. We hypothesize that PAP therapy will slow kidney function loss and that effective PAP therapy will slow kidney function loss to a greater degree than ineffective therapy. The Wisconsin Sleep Cohort Study (WSCS) is 20-year ongoing NIH-funded prospective study of 1,522 middle-aged healthy adults with periodic assessments of sleep apnea severity using gold-standard measures, measures of PAP therapy adequacy, and serial serum creatinine tests from which kidney function may be estimated. The KPSC Population Research Databases contain validated case-identification of over 100,000 sleep apnea patients, including diagnosis and PAP device dispensation dates, and complete electronic medical records that include clinically obtained serum creatinine tests. In both cohorts, kidney function will be assessed based on the estimated glomerular filtration rate (eGFR). We will model eGFR trajectory using linear slopes and non-linear mixed models to compare eGFR trend before and after PAP therapy. In each cohort, a non- apnea comparison group will be constructed and major comorbidities will be controlled. We intend this study to directly inform the conduct of a future effectiveness trial in which screening and therapy for sleep apnea is compared across intervention and non-intervention sites utilizing active and passive data collection in a large population, such as KPSC. The results of this study have the potential to push forward a promising area of research that eventually may alter the evaluation and treatment of patients at high renal risk or with established CKD to help prevent related morbidity and mortality.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PRN Blood Pressure Medication Use in VA Hospitals: A Mixed Methods Approach
  • 批准号:
    10424766
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2022
  • 负责人:
    Muna T Canales
  • 依托单位:
Sleep Disorders and Risk of ESRD, Death and Poor QOL in Veterans with CKD
  • 批准号:
    8698383
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    Muna T Canales
  • 依托单位:
Sleep Disorders and Risk of ESRD, Death and Poor QOL in Veterans with CKD
  • 批准号:
    8497428
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    Muna T Canales
  • 依托单位:
Sleep Disorders and Risk of ESRD, Death and Poor QOL in Veterans with CKD
  • 批准号:
    8331015
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2012
  • 负责人:
    Muna T Canales
  • 依托单位:
海外基金